DSP-7888 Dosing Emulsion is an investigational therapeutic cancer vaccine comprising two synthetic peptides derived from Wilms tumor 1 (WT1) to promote both cytotoxic T-lymphocyte and helper T-lymphocyte–mediated immune responses against WT1-expressing tumors.

DSP-7888, administered either intradermally or subcutaneously, was well tolerated in this phase I study of malignancies. No dose-limiting toxicities were observed.

Based on pharmacodynamic data, intradermal DSP-7888 was selected for further evaluation in advanced solid tumors, including glioblastoma.